Skip to main content

Drug Interactions between emicizumab and Feiba

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

anti-inhibitor coagulant complex emicizumab

Applies to: Feiba (anti-inhibitor coagulant complex) and emicizumab

MONITOR CLOSELY: Coadministration of emicizumab with activated prothrombin complex concentrate (aPCC) may increase the risk of thrombosis. Cases of thrombotic microangiopathy (TMA) and other thrombotic events have been reported when cumulative amounts greater than 100 U/kg/24 hours of aPCC was administered for 24 hours or more to patients receiving emicizumab prophylaxis. In two emicizumab efficacy trials, TMA was reported in 1.6% (3/189) and 8.3% of patients (3/36) who received at least one dose of aPCC. Evidence of improvement was seen within one week following discontinuation of aPCC. Thrombotic events were reported in 1.1% (2/189) and 5.6% of patients (2/36) who received at least one dose of aPCC. No thrombotic event required anticoagulation therapy, and evidence of improvement or resolution was seen within one month following discontinuation of aPCC.

MANAGEMENT: Close monitoring is recommended when activated prothrombin complex concentrate must be used during emicizumab prophylaxis. Immediately discontinue aPCC and suspend dosing of emicizumab if clinical symptoms, imaging, and/or laboratory findings consistent with TMA or thromboembolism occur, and manage as clinically indicated. Consider the benefits and risks of resuming emicizumab prophylaxis following complete resolution of TMA or thromboembolism on a case-by-case basis.

References

  1. (2017) "Product Information. Hemlibra (emicizumab)." Genentech

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer